Vir Biotechnology Files 8-K on Executive and Board Changes
Ticker: VIR · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1706431
| Field | Detail |
|---|---|
| Company | Vir Biotechnology, Inc. (VIR) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, filing
TL;DR
Vir Bio 8-K: Exec changes, board elections, comp plans filed 4/18 for 4/15.
AI Summary
Vir Biotechnology, Inc. filed an 8-K on April 18, 2024, reporting on events as of April 15, 2024. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes other events and financial statements/exhibits.
Why It Matters
This filing indicates potential shifts in leadership and governance at Vir Biotechnology, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers, especially if numerous or at senior levels, can signal underlying issues or strategic realignments that may affect the company's future performance.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- April 15, 2024 (date) — Date of earliest event reported
- April 18, 2024 (date) — Date of Report
FAQ
Who specifically departed from their roles at Vir Biotechnology?
The filing indicates the 'Departure of Directors or Certain Officers' as an item, but does not name the individuals in the provided text.
Were there any new directors or officers appointed?
Yes, the filing explicitly lists 'Election of Directors' and 'Appointment of Certain Officers' as reported items.
What is the primary business of Vir Biotechnology, Inc.?
Vir Biotechnology, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
When did the events reported in this 8-K filing occur?
The earliest event reported occurred on April 15, 2024.
What is the principal executive office address for Vir Biotechnology?
The principal executive offices are located at 1800 Owens Street, Suite 900, San Francisco, California 94158.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-04-18 08:44:31
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select
Filing Documents
- d824543d8k.htm (8-K) — 26KB
- d824543dex991.htm (EX-99.1) — 16KB
- g824543g0417115305740.jpg (GRAPHIC) — 2KB
- 0001193125-24-100072.txt ( ) — 171KB
- vir-20240415.xsd (EX-101.SCH) — 3KB
- vir-20240415_lab.xml (EX-101.LAB) — 18KB
- vir-20240415_pre.xml (EX-101.PRE) — 11KB
- d824543d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated April 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIR BIOTECHNOLOGY, INC. Date: April 18, 2024 By: /s/ Marianne De Backer Marianne De Backer M.Sc., Ph.D., MBA Chief Executive Officer and Director